K-Ras-PDEδ-IN-1 is primarily used in cancer research, specifically targeting the KRAS-PDEδ interaction, which plays a critical role in the localization and signaling of KRAS, a protein often mutated in various cancers. By inhibiting this interaction, the compound disrupts the proper membrane localization of KRAS, thereby impairing its oncogenic signaling pathways. This makes it a valuable tool for studying KRAS-driven cancers, such as pancreatic, lung, and colorectal cancers. Additionally, it serves as a potential lead compound for developing therapeutic agents aimed at treating cancers with KRAS mutations, which have historically been challenging to target. Its application extends to preclinical studies, where it helps elucidate the mechanisms of KRAS signaling and evaluate the efficacy of targeted therapies.